Rapamycin treatment reduces the incidence of T-cell lymphoma and leads to increased survival in myr-AKT mice. (A) Kaplan-Meier survival curve of myr-AKT mice given daily intraperitoneal injections of vehicle (n = 6) or 4 mg/kg rapamycin (n = 7), starting at 4 weeks after transplantation. The curve on the left represents overall survival, whereas the curve on the right shows the incidence of T-cell lymphoma, here defined as an enlarged thymus weighing more than 200 mg. (B) Organ weights of vehicle- and rapamycin-treated myr-AKT mice at the time of death. (C) Flow cytometric analysis of the myeloid lineages of BM and spleen (SP) single-cell suspensions from representative vehicle- and rapamycin-treated myr-AKT mice. All were gated for GFP⁺ cells. Values are mean ± SEM. *P < .05. (D) Percentage of GFP⁺ cells in the BM and spleen of vehicle- and rapamycin-treated myr-AKT mice.